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ABSTRACT
OBJECTIVE: High grade bladder cancer is extremely aggressive. Early detection is thus an important challenge. De-
velopment of non-invasive diagnostic tools particularly using urine samples could be of importance in the diagnosis and 
surveillance of these patients. Exosomes are small vesicles present in the urine and have the potential to be used as 
biomarkers of cancer. Thus studies of the properties and concentrations of these particles in bladder cancer patients 
are of importance.
MATERIALS AND METHODS: The concentration of exosomes present in urine was determined by nanoparticle tracking 
analysis using a Nanosight LM10 unit. Clinical urine samples were routinely collected and fixed using Preservcyt. The 
morphology of exosomes was studied in electron micrographs and characteristic exosome markers using Western blots.
RESULTS: The exosome concentration of fixed samples stored at room temperature was constant for 48 hours and the 
same as fresh samples. Exosomes derived from patients presenting for a transurethral resection of their bladder tumor 
exhibited the exosome markers ALIX and TSG101 and also the classic cup shaped appearance in electron micrographs. 
The concentration of exosomes in patients presenting for transurethral resection of a bladder tumor was significantly 
greater than in patients presenting for check cystoscopy with no recurrence (median 77.2 × 108 per ml compared with 
38.8 × 108 per ml, P < 0.001). A ROC analysis (area under the curve 77.4%) suggested that a suitable cut-off concen-
tration of 85 × 108 per ml is associated with a sensitivity of 43% and specificity of 91% for diagnosing bladder cancer. 
CONCLUSIONS: Thus the concentration and properties of exosomes can be conveniently studied in fixed urine sam-
ples derived from bladder cancer patients. The characteristic properties of exosomes were preserved and increased 
numbers were found in patients presenting for transurethral resection of their tumor. With an appropriate cut-off value, 
urinary exosome concentrations may have utility in excluding a cancer recurrence when monitoring patients successfully 
treated for bladder cancer.
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INTRODUCTION
Exosomes are small vesicles released from both normal and tumor 
cells and are found in large numbers in the blood and urine [1,2]. These 
vesicles contain proteins and RNA species and characteristic cell surface 
markers. Nanoparticle tracking analysis (NTA) has been widely used 
to determine the size profiles and concentrations of exosomes derived 
from both normal and tumor cells in culture [3,4]. Exosomes have a 
wide range of biological activity capable of modulating the immune 
response [5], inducing angiogenesis [6], modulating niche formation 
in metastasis [7] and influencing tumor growth [8,9].
As exosomes exhibit cell surface markers and contain microRNA, 
they present potential targets to be used as biomarkers of cancer [10,11]. 
Promising results have been reported for ovarian cancer [12] and for 
non-small cell lung cancer [13,14]. 
Bladder cancer represents an important challenge to early detection 
as high grade bladder cancer is extremely aggressive. Beckham et al. 
[15] have demonstrated that bladder cancer derived exosomes from both 
cell lines and urine of patients promote angiogenesis and bladder cancer 
migration. They also showed that bladder cancer derived exosomes 
contained high concentrations of EDIL-3 relative to exosomes derived 
from healthy controls. Silencing of EDIL-3 expression blocked the 
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angiogenic and tumor migratory effects of bladder cancer derived exo-
somes. Similarly Chen et al. [16] have identified the protein TACSTD2 
in association with bladder cancer exosomes and further demonstrated 
a strong association with bladder cancer on analysis of urine samples.
Thus the analysis of exosomes from easily accessible and routinely 
collected urine samples has potential as a new tool in bladder cancer 
studies.
MATERIALS AND METHODS
Collection and processing of urine samples
Urine samples were collected from patients presenting for check 
cystoscopy (Table S2) or for transurethral resection of a bladder cancer 
(Table S1). Preservcyt (Cytec, UK) was added (2:1 urine Preservcyt) to 
the samples for analysis of exosome numbers. Samples were obtained 
with informed consent (LREC 07/S1402/48). All samples were analysed 
within 48 hours of fixation.
Analysis of exosome concentration
Exosome concentrations were determined using a Nanosight LM10 
analysis unit with a 645 nm laser (Nanosight, Salisbury, United King-
dom). The urine samples were spun initially at 300 × g for 10 min 
to remove any cells and debris, followed by centrifugation in 1.5 ml 
Eppendorf tubes at 20,000 × g for 20 min to remove large vesicles. The 
resultant supernatants were diluted appropriately to give counts in the 
linear range of the instrument (i.e., 3 × 108 to 109 per ml). Videos of the 
particles undergoing Brownian motion in the laser beam were recorded 
and analysed using the Nanosight Tracking Analysis software (NTA 
2.3) which determines the exosome concentration and size distribution. 
Three videos of 30 sec duration were recorded for each sample with a 
shutter speed setting of 1500 (exposure time 30 ms) and camera gain 
of 560. For analysis the detection threshold was set at 6 and at least 
1000 tracks were analysed for each video.
Western blotting
The fixed urine samples were spun at 300 × g for 10 min followed 
by centrifugation at 10,000 × g for 1 hour and then 100,000 × g for 2 
hours at 4ºC on a Beckman Coulter Optima L-100×P ultracentrifuge 
to collect a pellet of exosomes before determining total protein content 
using the Bicinchoninic acid (BCA) assay. The concentrated samples of 
exosomes were then suspended in reducing buffer, denatured for 60 min 
at 60ºC, separated by 10% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and then finally transferred to Immobilon-P 
PVDF membranes (Millipore: IPVH00010). After transfer, the mem-
branes were blocked in LiCor Blocking Buffer (diluted 50:50 in PBS) 
for 1hr at room temperature before incubating with primary antibodies 
overnight at 4ºC. Antibodies used were as follows: Alix (Santa Cruz; 
sc53538 at 1:1000), TSG101 (Santa Cruz; sc7964 at 1:1000), MCM2 
(Cytosystems; 1:1000), CD9 (Santa Cruz; sc51575 at 1:1000) and actin 
(Abcam; ab8227 at 1:2000). Detection was then carried out by first 
washing membranes in 0.1% PBS-Tween20 (3 × 5 min) followed by a 
45 min incubation at room temperature with fluorescently-labelled Goat 
anti-Mouse IRDye 800CW secondary antibody (LiCor; 926-32210) 
at 1:10,000 dilution in LiCor Blocking Buffer (diluted 50:50 in PBS) 
containing 0.01% SDS. After further washing in 0.1% PBS-Tween20 
(3 × 5 min) and PBS (3 × 5 min), visualisation was carried out using 
a LiCor Odyssey Scanner.
Transmission electron microscopy
For ultrastructural analysis, samples were adsorbed onto piolo-
form-coated 100 mesh copper grids (Agar Scientific, Stansted, UK), 
washed three times with MilliQ water, followed by contrasting and 
embedment in 3% (w/v) uranyl acetate/2% (w/v) methyl cellulose 
(mixed 1.5:9, see Lucocq et al. [17]). The dried samples were analysed 
using a JEOL 1200-EX transmission electron microscope operated at 
80kv and images taken using a Gatan Orius 200 digital camera (Gatan, 
Abingdon, Oxon, UK) at a nominal magnification of 2000 or 3000×. 
Exosomes were identified by the presence of a complete or partial 
membrane profile and images were selected using systematic uniform 
random sampling [18].
Statistical analysis
The results have been expressed as mean ± standard error. Differ-
ences between the groups were considered significant at P < 0.05. Data 
were interpreted using one way analysis of variance and unpaired t test 
using Welch’s correction when variances were significantly different. 
The concentration of exosomes in cancer and non-cancer patients were 
subjected to a receiver operating characteristic (ROC) curve to determine 
an optimum cut-off value associated with presence of a bladder tumor.
RESULTS
Urine was collected from 37 patients with Transitional Cell Carcinoma 
(TCC) and 79 patients attending for check cystoscopy but who did not 
have evidence of recurrence or inflammatory changes in the bladder. 
The average age of the 37 patients with TCC was 75 years (40–94, SD 
= 12.1) and the 79 patients attending for check cystoscopy was 71 years 
(42–92, SD = 10.8). Of the 37 patients with TCC 70% were male and in 
the check cystoscopy group 62% were male. Exosome concentrations 
were determined in urine samples after appropriate centrifugation us-
ing the Nanosight Analysis unit and software. Different volumes of a 
urine sample were made up to 1 ml in sterile DPBS thus giving defined 
dilutions. A linear relationship between the concentration of exosomes 
per ml and the dilution was established (Fig. 1). 
Exosome concentrations were also determined in nine freshly collect-
ed urine samples and followed in the same samples after fixation (2:1 
urine/Preservcyt) for 48 hours. There was no difference in the exosome 
concentration between the samples analysed at 2, 24 and 48 hours (Fig. 
2, one way analysis of variance P = 0.71 with equal variances for each 
time point P = 0.96). 
The size range of exosomes indicated the typical profile of microve-
sicles with a size range of 50–300 nm with peak concentrations in the 
100–140 nm range (Fig. 3). 
Analysis of cell surface markers on exosomes from 5 patients with 
bladder cancer (L15, L24, L25, L27 and L30) using Western blots 
demonstrated the presence of ALIX and TSG101 as characteristic 
markers of exosomes (Fig. 4).
The exosomes also exhibited the characteristic cup shaped pattern 
when observed in samples fixed for electron microscopy (Fig. 5). Sam-
ples L7 and L14 were from control patients without bladder cancer and 
L18 and L23 from patients with bladder cancer.
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Figure 1. Exosome concentration in a urine sample measured using 
the Nanosight LM10 showing a linear relationship when diluted (3 
replicates, Y = (9.1 × 106)X + (0.68 × 108).
Figure 2. The exosome concentration, as a percentage of the 
concentration of the unfixed sample at time 0, was compared in 
fixed urine samples at 2, 24 and 48 hours after fixation for urines 
collected from 9 healthy controls.
Figure 3. Examples of the size 
profiles of exosomes analysed 
on the Nanosight LM10. A and 
B. Profiles of urinary exosomes 
collected from patients with blad-
der cancer. C and D. Profiles from 
patients presenting at check cys-
toscopy and found not to have a 
recurrence.
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Figure 5. Transmission 
electron micrograph of 
exosomes in urine sam-
ples derived from L7 and 
L14 patients presenting for 
check cystoscopy without 
a recurrence of bladder 
cancer and L18 and L23 
patients presenting with 
bladder cancer.
Figure 4. Examples of 
Western blots demon-
strating the presence of 
characteristic exosome 
markers.  A. ALIX (pre-
dicted molecular weight of 
100kDa). B. Tsg101 (predict-
ed molecular weight of 45 
kDa) on exosomes collected 
from the urine of 5 patients 
with bladder cancer.
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Table 1. Exosome concentrations in urine of patients with bladder cancer and patients presenting for check cystoscopy and found to have no 
evidence of a recurrence.
Exosome concentration (× 108/ml)
Bladder cancer 
(n = 37)
Check cystoscopy – negative for TCC 
(n = 79)
Mean 111.4 45.6
Median 77.2 38.8
Standard deviation 107.4 23.3
Standard error 17.7 2.6
Minimum inter-quartile range 25.3 7.3
Maximum 482.3 121.4
inter-quartile range 49.6–115.0 30.5–55.1
Figure 6. Concentration of exosomes in urine samples collected from 
patients presenting for check cystoscopy without a recurrence (con-
trol patients) and patients with bladder cancer (patients presenting 
for TURBT).
Figure 7. Receiver operating characteristic curve for urine concen-
tration of exosomes.
The distribution of concentration of exosomes differed between 
patients with a known tumor presenting for a transurethral resection 
of their bladder tumor and patients presenting for a check cystoscopy 
with no evidence of a recurrence (Fig. 6, Table 1). The concentration 
of exosomes was log transformed and that in cancer patients was 
significantly greater than that in control patients (t = 5.13, df 53, P < 
0.001 unpaired t-test using Welch’s correction as variances differed 
significantly). 
The ROC analysis (Fig. 7) yielded an area under the curve (C-sta-
tistic) of 0.774 (95% CI 0.678 to 0.871). The optimum cut-off exosome 
concentration associated with a diagnosis of bladder cancer was 85 × 
108 per ml which had a sensitivity of 43.2% and specificity of 92.4%.
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DISCUSSION
Most current methods for the analysis and quantification of exosomes 
are time consuming and semi-quantitative. Nanoparticle tracking analysis 
assesses the concentration and size distribution of particles from a video 
recording of the particles moving under Brownian motion. Exosomes 
can be conveniently analyzed in urine samples using this method [19]. 
In our study, we have demonstrated that exosome concentrations can 
be assessed in fixed urine samples routinely collected in the clinic. 
Samples need to be centrifuged to remove cells and debris and larger 
particles but this is a rapid and simple step. The sample is then diluted 
in phosphate buffered saline to allow appropriate quantification in the 
Nanosight, as the particle concentration needs to be in the linear range 
of the instrument (i.e., 3 × 108 to 109 per ml, [20]). The concentration 
of exosomes does not change over a 48 hour period after collection and 
fixation compared to the freshly collected unfixed urine sample. Simi-
larly if a sample is diluted then there is a linear relationship between the 
exosome concentration and the dilution. Thus exosome concentrations 
can be conveniently assessed in fixed urine samples with minimal pro-
cessing. This means that urine samples can be collected and analysed 
without the patient having to attend a urology clinic.
The size profile of the urinary exosomes is similar to those reported 
by others [21]. Established exosome markers were also detected on 
the fixed urinary exosomes [22,23]. The exosomes also exhibited the 
characteristic cup shape reported in the literature [24].
Urinary exosomes will be derived from a variety of sources including 
the kidney and bladder so quantification of exosomes from a specific 
tissue is not possible so far. Exosome concentrations in the urine of a 
cohort of bladder cancer patients were, on average, significantly increased 
compared to concentrations in patients presenting for cystoscopy and 
found not to have a recurrence.
Diagnosis of bladder cancer relies on cystoscopy or urine cytology. 
However urine cytology has low specificity [25]. Thus there is a need 
to develop non invasive methods to detect bladder cancer. Our results 
suggest measuring exosome concentration may have much higher 
specificity (91.1%) though, at an optimum cut-off value of 85 × 108, 
sensitivity was only 43.2%. However, a lower cut-off value could be 
adopted to exclude cancer in patients being monitored for a cancer 
recurrence in order to avoid an otherwise unnecessary cystoscopy. 
Further studies are warranted investigating such outcomes and relative 
costs associated with measuring urinary exosome concentrations and 
repeat cystoscopies in patients being monitored for bladder cancer re-
currence. Further studies also need to be undertaken to investigate the 
significance of patients with CIS and patients with positive cytology 
but without visible disease. A larger cohort of patients would allow 
comparisons of patients with high grade bladder cancer with other 
grades and comparisons of superficial versus muscle invasive disease.
Tumor markers on urinary exosomes have been found to be useful 
in the detection of lung cancer [26] and prostate cancer [27,28]. The 
potential of using biomarkers on urinary exosomes for the detection of 
bladder cancer has been reviewed by Blackwell et al. [29] and potential 
markers identified.
Exosomes derived from tumors also play a key role in modifying tu-
mor behavior. Exosomes derived from a bladder cancer cell line (SW780 
cells) are internalized by cancer cells [30]. We have also shown that 
human breast cancer cells also internalize exosomes derived from human 
breast cancer lines and also from normal human mammary epithelial 
cells [4]. The release of exosomes from both normal cells and breast 
cancer cells is regulated by the presence of exosomes from these cells 
in the extracellular environment. Thus there is a feedback mechanism 
regulating the release of exosomes [4]. Exosomes also promote the 
migration of urothelial cells and angiogenesis [15]. Proliferation of 
bladder tumor cells is promoted by exosomes and apoptosis is inhibited 
[31]. Thus it is clear that exosomes are key players in interacting with 
tumor cells and require further study.
CONCLUSIONS
This study investigates the properties and concentrations of exosomes 
present in fixed urine samples from patients presenting for check cystos-
copy and found not to have a recurrence and patients with bladder cancer 
presenting for transurethral resection of the tumor. Exosome concentra-
tions can be determined in fixed urine samples using a Nanosight LM10 
analysis unit. There is no difference in the concentration of exosomes in 
fresh samples compared to samples that are fixed and measured up to 
48 hours later. The fixed exosomes exhibit the characteristic exosome 
markers, ALIX and TSG101, and have the characteristic cup shaped 
form as observed in transmission electron micrographs. There was a 
significant increase in exosome concentration of a group of patients 
presenting for bladder tumor resection compared to patients presenting 
for check cystoscopy without a recurrence and, with an appropriate 
cut-off, the test may have clinical utility for excluding a recurrence in 
patients in follow-up. As exosome concentrations are constant over a 48 
hour in fixed samples, the patient can provide a sample without having 
to attend a urology clinic. Thus evaluating the properties of exosomes 
in fixed urine samples may be of value in screening for tumor markers 
in patients presenting for cystoscopy.
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